PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 14, 2026Neurological Research and Practice0 citationsOpen Access

Rethinking EDSS-based ambulation assessment in multiple sclerosis using continuous variable monitoring

NWNoah M. WernerMSMelanie SchuetteRHRamona Hagler

Key Points

  • This research aims to evaluate the effectiveness of continuous monitoring using digital health technologies in assessing walking ability in multiple sclerosis patients.
  • Prospective observational study across two centers in Germany
  • Patients with relapsing-remitting MS underwent clinical assessments and continuous activity monitoring using smartwatches
  • Walking distance and step counts were measured at baseline and study completion.
  • Patient-estimated walking distance showed moderate correlation with measured distance (Spearman's ρ = 0.60, p = 0.013)
  • Median daily walking distance correlated negatively with EDSS scores (ρ = −0.61, p = 0.0123)
  • Step count negatively correlated with EDSS scores (ρ = −0.64, p = 0.0082) and peak steps (ρ = −0.69, p = 0.0032).

Abstract

Abstract Background Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) characterized by relapses and progressive disability. The Expanded Disability Status Scale (EDSS), used to quantify disability, is based on single, discretely assessed and potentially inaccurate patient-estimated walking ability, whereas digital health technologies (DHTs) enable continuous activity monitoring and more objective assessment of real-world functional performance. Methods In this prospective observational study conducted at two German centers, patients with relapsing-remitting MS (RRMS) underwent clinical assessments at baseline (V1) and study completion (V2). Walking distance and step counts were measured using a measuring wheel and pedometer, while continuous physical activity was assessed via smartwatch-derived metrics. Results Sixteen patients with RRMS were included (median age 57.5 years interquartile range (IQR) 49.25–63.25; median EDSS 4.5 IQR 3.5–6). Patient-estimated walking distance at V1 showed moderate correlation with clinically measured distance (Spearman‘s ρ = 0.60, p = 0.013), with 12 of 16 patients misjudging distances relative to EDSS thresholds. Walking distance showed intra-individual variability between V1 and V2 (median absolute difference: 113.6 m). Median daily walking distance (ρ = −0.61, p = 0.0123), step count (ρ = −0.64, p = 0.0082), and peak steps (ρ = −0.69, p = 0.0032) correlated negatively with EDSS. Conclusion Patient-estimated maximum walking distance demonstrated moderate agreement with clinical performance and frequently crossed EDSS thresholds, while clinical assessments varied substantially within individuals over the short study duration, underscoring the limitations of single evaluations. In contrast, smartwatch-derived metrics aligned with clinical measures, reflected EDSS scores, and captured real-world mobility.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Werner et al. (2026) studied this question.

synapsesocial.com/papers/6a2e46b3b1cc60ccdea8b515https://doi.org/10.1186/s42466-026-00501-8
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diurnal step count patterns in progressive multiple sclerosis2026
  2. 2Feasibility of Privacy-Preserving LiDAR-Based Continuous Gait and Activity Monitoring in Three People with Multiple Sclerosis: A Technical Proof-of-Concept Case Study2026
  3. 3Real-life walking speed: A new marker of progression in a primary progressive multiple sclerosis cohort study?2026
  4. 4Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study—lessons learnt, baseline demographics and clinical characteristics2026 · 2 citations
  5. 5Anchor-based evaluation of digital motor biomarkers from a 2-year observation in 100 patients with multiple sclerosis2025